Last reviewed · How we verify

NCT07294404

Peripheral Relative Refractive Power of Orthokeratology Lenses

Completed Last updated 2 March 2026
What this trial tests

trial testing orthokeratology in Myopia in 53 participants. Completed in 19 October 2021.

Timeline
10 January 2020
Primary endpoint
15 June 2021
19 October 2021

Quick facts

Lead sponsorTianjin Eye Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment53
Start date10 January 2020
Primary completion15 June 2021
Estimated completion19 October 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Tianjin Eye Hospital

Who can join

Adults 8 to 15, any sex, with Myopia or Myopia; Refractive Error. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Orthokeratology (OK) has been demonstrated to be an effective intervention for slowing axial elongation in children with myopia. The proposed mechanism of action is the induction of peripheral myopic defocus, which reduces relative peripheral hyperopia on the retina. This study aims to evaluate changes in relative peripheral retinal refraction before and after OK lens wear using wide-field multispectral retinal refractive topography. The study will also investigate the relationship between these retinal refractive changes and the effectiveness of OK in controlling axial elongation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of orthokeratology

Trials testing the same drug.

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Tianjin Eye Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07294404.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing